Relmada Therapeutics, Inc. Common Stock (RLMD)
PHARMACEUTICAL PREPARATIONS
Relmada Therapeutics, Inc. Common Stock (RLMD) is listed on Nasdaq, where it has traded since March 3, 2014.
- Listed On
- Nasdaq
- Listed Since
- March 3, 2014
- Employees
- 17
- Market Cap
- $409M
About Relmada Therapeutics, Inc. Common Stock
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 123 institutions reported holding RLMD, with 100.2 million shares worth $693.7 million in aggregate. The largest reported holder was Jupiter Topco, with 11.2 million shares worth $77.3 million. Of the 5 largest holders listed below, 1 opened a new position in RLMD, 3 added shares and 1 reduced its position during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Jupiter Topco | 11,164,803 | $77M | New position |
| BlackRock | 7,426,780 | $51M | Added 475.92% |
| Squadron Capital Management | 7,350,000 | $51M | Reduced 13.27% |
| VR Adviser | 6,844,305 | $47M | Added 41.31% |
| Spruce Street Capital | 6,391,328 | $44M | Added 2.06% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is RLMD?
Relmada Therapeutics, Inc. Common Stock (RLMD) is listed on Nasdaq, where it has traded since March 3, 2014.
Who are the largest institutional holders of RLMD?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of RLMD were Jupiter Topco, BlackRock and Squadron Capital Management.
How many institutions own RLMD?
123 institutions reported a position in RLMD for the quarter ended June 30, 2026, worth $693.7 million in total.
Did institutions buy or sell RLMD last quarter?
Of the 5 largest reported holders, 1 opened a new position in RLMD, 3 added shares and 1 reduced its position during the quarter. Every reported holder and its change is on the SentiSense ownership page for RLMD.
Every reported institutional holder, plus insider and congressional trades in RLMD, on SentiSense.